Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $76.17 Average Target Price from Analysts

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) have received a consensus rating of "Buy" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued a report on the stock in the last year is $76.17.

A number of research firms have weighed in on GPCR. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd. JMP Securities reissued a "market outperform" rating and issued a $89.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. Citigroup began coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 target price on the stock. Finally, HC Wainwright dropped their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research report on Monday, May 12th.

Structure Therapeutics Stock Performance

Structure Therapeutics stock traded up $0.18 during mid-day trading on Thursday, reaching $20.62. The company's stock had a trading volume of 372,490 shares, compared to its average volume of 837,274. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $47.48. The business's 50 day simple moving average is $23.15 and its 200 day simple moving average is $23.43. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -23.70 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, sell-side analysts expect that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC lifted its holdings in Structure Therapeutics by 5.1% during the 4th quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock valued at $112,816,000 after purchasing an additional 203,010 shares during the last quarter. Deep Track Capital LP raised its position in shares of Structure Therapeutics by 129.4% in the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock valued at $75,936,000 after purchasing an additional 1,579,492 shares during the period. Vestal Point Capital LP raised its position in shares of Structure Therapeutics by 3.7% in the first quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock valued at $30,967,000 after purchasing an additional 63,990 shares during the period. Capital International Investors lifted its stake in shares of Structure Therapeutics by 6.8% during the 4th quarter. Capital International Investors now owns 1,619,081 shares of the company's stock worth $43,909,000 after buying an additional 103,059 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Structure Therapeutics by 29.4% during the 4th quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock worth $38,512,000 after buying an additional 322,601 shares during the period. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.